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Abstract 36 
Background: Patients undergoing radical cystectomy have associated comorbidities 37 
resulting in reduced cardiorespiratory fitness.  Preoperative cardiopulmonary exercise 38 
testing (CPET) measures including anaerobic threshold (AT) can predict major 39 
adverse events (MAE) and hospital length of stay (LOS) for patients undergoing open 40 
and robotic cystectomy with extracorporeal diversion. Our objective was to determine 41 
the relationship between CPET measures and outcome in patients undergoing robotic 42 
radical cystectomy and intracorporeal diversion (iRARC). 43 
Methods: A single institution prospective cohort study in patients undergoing iRARC 44 
for muscle invasive and high grade bladder cancer. Inclusion: patients undergoing 45 
standardised CPET prior to iRARC. Exclusions: patients not consenting to data 46 
collection. Data on CPET measures (AT, ventilatory equivalent for carbon dioxide 47 
(VE/VCO2) at AT, peak oxygen uptake (VO2)), and patient demographics 48 
prospectively collected. Outcome Measurements included Hospital LOS; 30-day 49 
MAE and 90-day mortality data, which were prospectively recorded. Descriptive and 50 
regression analyses were used to assess whether CPET measures were associated with 51 
or predicted outcomes.  52 
Results: From June 2011 to March 2015 128 patients underwent radical cystectomy 53 
(ORC n=17, iRARC n=111). 82 patients who underwent iRARC and CPET and 54 
consented to participation were included. Median (IQR): Age=65 (58−73); BMI=27 55 
(23−30); AT=10.0 (9−11), Peak VO2=15.0 (13−18.5), VE/VC02 (AT)=33.0 (30−38). 56 
30-day MAE=14/111 (12.6%): Death=2, Multi organ failure=2, abscess=2, 57 
Gastrointestinal=2, Renal=6; 90-day mortality=3/111 (2.7%). AT, Peak VO2, 58 
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VE/VC02 (at AT) were not significant predictors of 30-day MAE or length of stay. 59 
The results are limited by the absence of control group undergoing open surgery. 60 
Conclusions: Poor cardiorespiratory fitness does not predict increased hospital LOS 61 
or MAEs in patients undergoing iRARC. Overall, MAE and LOS comparable with 62 
other series.  63 
 64 
Keywords 65 
Anaerobic threshold, Cardiopulmonary exercise testing, Cardiorespiratory, 66 
Complications, Length of stay, Muscle invasive, Radical cystectomy, Robotic, 67 
Urothelial carcinoma. 68 
 69 
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1. Introduction 71 
The incidence of bladder cancer increases with age and is associated with smoking 72 
and exposure to industrial carcinogens. Consequently, pre-morbid conditions that lead 73 
to reduced performance status, such as cardiovascular disease, are apparent in the 74 
treated population (1).  Radical cystectomy with urinary diversion remains the gold 75 
standard treatment for muscle invasive bladder cancer and non-muscle invasive 76 
disease in selected patients.   Following radical cystectomy, the major adverse event 77 
rate is around 15% and the 90-day mortality is between 1.7% and 9%, both of which 78 
reflect the impact of surgery in a patient group with reduced performance status (2‒4).  79 
 80 
A number of methods exist to measure performance status with the intention to 81 
predict post-operative adverse events and their use is recommended prior to major 82 
surgery (5−8).  Tools such as the American Society of Anaesthesiologists (ASA) 83 
index, Charlson comorbidity index, Eastern Cooperative Oncology Group (ECOG) 84 
performance index can be used to assign risk for major complication and mortality 85 
following radical cystectomy.  Another method, cardiopulmonary exercise testing 86 
(CPET) has the distinct advantage of measuring the efficiency of physiological 87 
oxygen exchange, and therefore cardiorespiratory function (CRF) for the individual 88 
being tested. This allows clinicians to create a personalised risk profile with which to 89 
predict post-operative morbidity and mortality (9,10). Systemic complications that 90 
occur following major surgery arise in part as a result of the inability of patients with 91 
poor CRF to meet the increased peri-operative oxygen demand which arises as a 92 
result of a systemic inflammatory response (11,12). Measuring the peak oxygen 93 
uptake (Peak VO2) during exercise, the threshold at which anaerobic respiration 94 
begins to supplement aerobic respiration, the anaerobic threshold (AT), and the peak 95 
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VO2 and ventilatory equivalent for carbon dioxide (VE/VCO2) which gives a measure 96 
of pulmonary efficiency can predict post-operative morbidity and mortality 97 
(10,13−15). Patients with a poor CPET result are at much higher risk of peri-operative 98 
cardiac morbidity and death (9,10,13−15). Variables derived from CPET including 99 
anaerobic threshold (AT) and VEO2 are predictive of major complications and length 100 
of stay following open cystectomy (ORC) and also RARC with extracorporeal 101 
diversion (eRARC) (14,15).  102 
 103 
We sought to determine the association between cardiorespiratory fitness, as 104 
measured by CPET, and major complications or hospital LOS in patients undergoing 105 
iRARC. Our hypothesis was that the described CPET measures (AT and VEO2) 106 
which are predictive of outcome for ORC and eRARC should also predict outcome in 107 
patients undergoing iRARC (14,15). 108 
 109 
2. Patients and Methods 110 
2.1. Patients 111 
Over a 45-month period 128 patients underwent radical cystectomy at a single pelvic 112 
uro-oncology centre.  17 patients underwent planned ORC: 7 patients had previous 113 
pelvic or perineal surgery, 2 had radiotherapy for prostate cancer, 2 patients had 114 
clinical T4 stage, 4 patients had a concurrent procedure and 2 patients were 115 
randomized to open surgery as part of a randomized controlled trial comparing open 116 
cystectomy to minimal invasive cystectomy (BOLERO) (NCT01196403). iRARC 117 
was performed in the remaining 111 cases (Figure 1). CPET was performed on 118 
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iRARC patients before cystectomy (median 34 days). Technical aspects of iRARC 119 
have been previously described (16,17).   120 
 121 
2.2. Ethics 122 
All patients gave written informed consent for the results of their CPET to be stored 123 
on an institutional data base. Local Research Ethics Committee approval was given 124 
for the collection of CPET data on an institutional database (Reference: 12/LO/0192). 125 
 126 
2.3. CPET 127 
CPET was conducted on a cycle ergometer (Lode Corival) with continuous side 128 
stream gas exchange analysis (Cortex Metalyzer 3B). Patient demographics were 129 
recorded and patients’ activity level used to determine work rate. Spirometry was 130 
performed and haemoglobin measured using the Hemocue system. 12-lead ECG 131 
electrodes, pulse oximeter and blood pressure cuff were applied. Three minutes of rest 132 
preceded the test during which oxygen and carbon dioxide concentration along with 133 
gas flow were measured. Three minutes of unloaded cycling at 60−65 RPM was then 134 
undertaken. The work rate increases continuously thereafter until the test was 135 
terminated due to symptoms, volitional fatigue or ECG changes. The patient’s 136 
recovery was monitored until heart rate, blood pressure, ECG and saturations returned 137 
to baseline levels. CPET costs £225 ($320) and is reimbursed to the Department of 138 
Urology from the UK NHS tariff for cystectomy using service line reporting.   139 
 140 
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Ventilatory equivalents at AT were calculated using standard methods (19). VO2 peak 141 
was measured as the average VO2 attained over a 30 second period at peak exercise. 142 
All CPET variables were determined on the day of the test and then independently 143 
verified by a Consultant Anaesthetists with CPET expertise (RS). 144 
 145 
2.4. Peri-operative care 146 
All patients underwent a standardised perioperative protocol including formal pre-147 
operative assessment, on which CPET measures had no influence. This included 148 
carbohydrate loading on the evening prior to and morning of surgery, epidural 149 
anaesthesia, postoperative anti-emetics, histamine H2-antagosists (ranitidine), venous 150 
thromboembolic disease prophylaxis (Dalteparin), regular intravenous paracetamol 151 
analgesia and chewing gum (patients’ preference) three times daily for four days post-152 
op to stimulate gut motility. Post-operatively all patients went to the post-anaesthetic 153 
recovery unit (PACU) for a minimum of 24 hours, during which they received high 154 
dependency unit type care. The decision to extend PACU care or return the patient to 155 
the ward after the initial period was made by a critical care consultant independently 156 
of the surgical or anaesthetic teams. 157 
 158 
2.5. Data collection 159 
Patients were included in this study following written consent for their CPET results 160 
to be added to the institutional research database.  Patient demographics (age, height, 161 
weight, comorbidities and medication) and CPET measures were recorded. Post-162 
operative complications as defined by the Clavien-Dindo (CD) scoring system (a 163 
score of ≥3 counted as a major complication), and length of stay (LOS) were 164 
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prospectively recorded.  Following discharge, patients were reviewed in clinic by the 165 
surgical team approximately four weeks post-operatively. 166 
 167 
2.6. Statistical analysis 168 
Data is presented as percentages or median with interquartile range (IQR). 169 
Comparisons between independent groups were analysed using the non-parametric 170 
Mann-Whitney U-test and Kruskal-Wallis H-test for continuous variables, and Chi-171 
squared Test for categorical variables. Correlation between data sets was analysed 172 
using Spearman’s Rank Correlation. Multivariate binary logistic regression analysis 173 
was applied to identify potential factors associated with post-operative complications. 174 
Multivariate linear regression analysis was applied to identify potential factors 175 
associated with length of stay. Significance value was taken as less than 5% then 176 
adjusted for multiple comparisons using the Bonferroni correction. Statistical analysis 177 
was performed using SPSS software (version 21 for Windows, IBM, New York, 178 
USA). 179 
 180 
3. Results 181 
Between 1st June 2011 and 24th March 2015, 111 patients underwent iRARC and 82 182 
gave consent for their data to be placed on the CPET database.  Demographic details 183 
and summary CPET outcomes/data are presented in Table 1. The median length of 184 
stay was 10 days (IQR=6), there were 14 major complications within 30 days 185 
(12.6%), and three deaths (2.70%) within 90 days, one cancer related (0.9%) and two 186 
following major complications (1.8%). Details of major complications are presented 187 
in Table 2. Eight of the 14 major adverse events were categorised as being either a 188 
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direct result of the surgical technique (technical) or attributed to other organ or system 189 
failure, (non-technical) (n=6). 190 
 191 
No significant difference was found in AT, Peak VO2, or VE/VC02 (@AT) between 192 
patients who had complications and those who did not (Table 3). On multivariate 193 
logistic regression analysis none of these CPET parameters were significant predictors 194 
of a major complication at 30 days (Table 3). No significant correlation was found 195 
between length of stay and either of AT, Peak VO2, or VE/VCO2 (@AT). Using 196 
multivariate linear regression, CPET was not found to predict length of stay. (Table 3) 197 
 198 
Previously, for cases undergoing ORC or eRARC an AT of 12 and 11 have been 199 
defined as a threshold below which patients were at risk of increased LOS and 200 
occurrence of major complication (14,15).  Applying an AT threshold of 11 or 12, we 201 
found no significant difference between patients above and below this threshold in 202 
length of stay or major complications at 30 days. (Table 4). Additional analysis found 203 
no association between major complications at 30-days and ASA level (χ2(3) =7.083, 204 
p=0.069; Chi Squared-test), nor between hospital length of stay and ASA level (χ2(3) 205 
=6.874, p=0.076; Kruskal-Wallis H-test). Data on length of surgery was available for 206 
36/82 cases. Univariate analysis found no association between major complications at 207 
30-days and length of surgery (Z=-1.031, p=0.303; Mann-Whitney U-test), nor 208 
between hospital length of stay and length of surgery (ρ=0.157, p= 0.360; Spearman’s 209 
Rho test). 210 
 211 
212 
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4. Discussion 213 
This is the first study to examine the relationship between cardiopulmonary 214 
performance status and adverse events in patients undergoing iRARC. The results of 215 
this prospective study in an unselected cohort of patients undergoing iRARC suggest 216 
that in our population, the post-operative adverse event rate for major complications 217 
following iRARC is 12.6%, which compares favorably to that described in previous 218 
series (4).   219 
 220 
Contrary to the findings of Tolchard et al and Prentis et al, in which CPET (AT=11 221 
and AT=12) is highly predictive of major post-operative adverse events and LOS, we 222 
found no significant relationship between CPET and these outcomes. We did find 223 
weak association between CPET and hospital LOS but this was not significant, and 224 
the defined CPET parameters for ORC and eRARC are neither predictive nor 225 
associated with the occurrence of major adverse events in patients undergoing 226 
iRARC. The results suggest that patients undergoing iRARC with a reduced 227 
performance status, as assessed by CPET to reflect cardiopulmonary fitness, are not at 228 
the same level of risk for a post-operative adverse event as patients undergoing ORC 229 
or RARC converted to open surgery for reconstruction, as described previously 230 
(14,15). In the study by Prentis and colleagues, 82 patients undergoing radical 231 
cystectomy had CPET. They found that the occurrence of complications was 232 
associated with length of stay, which is consistent with our own data. They also found 233 
that AT was the only independent predictor of an adverse event post cystectomy and 234 
that a threshold of 12 was discriminated between ‘fit’ and ‘unfit’ patients i.e. those 235 
who were less likely and more likely to have complications (14). Similarly, Tolchard 236 
and colleagues assessed the relationship between CPET and complications after 237 
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radical cystectomy in 105 patients undergoing open or RARC. They found AT was 238 
negatively, and VE/VCO2 positively correlated with complications and LOS (15).  239 
Both of the studies above reported data from cohorts similar to our own with highly 240 
significant results (Table 5). We suggest that the utilisation of a truly minimally 241 
invasive approach may off-set the morbidity of the procedure and reduce the risk of 242 
complications that arise from major abdominal surgery in the presence of poor 243 
cardiorespiratory reserve. Other studies of intracorporeal reconstruction, notably the 244 
recent series of 128 cases of robotic intracorporeal neobladder by Desai and 245 
colleagues showed similar rates of complications, and the authors have drawn similar 246 
conclusions to our own (19).  247 
 248 
Systemic complications that occur following major surgery arise, in part, as a result of 249 
the inability of patients with poor CRF to meet the increased peri-operative oxygen 250 
demand (11,12). It is well documented that surgical trauma induces a systemic stress 251 
response which includes stimulation of the hypothalamic-pituitary-adrenal axis and 252 
the release of a humoral mediator response, such as cytokines, proportional to the 253 
severity of surgical stress. There is evidence in cystectomy and other surgical 254 
procedures that minimally invasive surgery provokes a lesser perioperative stress 255 
response with a diminished neuroendocrine-metabolic effect (20,21). It is interesting 256 
to speculate that the physiological stress response associated with minimally invasive 257 
cystectomy and intracorporeal reconstruction will be less than that of extracorporeal 258 
reconstruction or open surgery.   259 
 260 
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The results of the present study should be interpreted in light of certain limitations.  261 
This is a prospective cohort study and not a randomised comparator study.  We have 262 
however accounted for potential confounding factors such as age, gender, BMI, type 263 
of diversion, and use of neo-adjuvant chemotherapy in regression analysis. A further 264 
limitation of this study is the lack of sample size calculation prior to analysis. A 265 
possible criticism of the lack of significant association between CPET measures and 266 
outcomes might be that potential differences were missed due to the study being 267 
underpowered. The sample in this study is similar in size and clinical setting to those 268 
of previous studies and as such we feel that our findings are of relevance to the 269 
literature on robotic cystectomy. Furthermore, as iRARC is standard practice within 270 
our institution, the effect of case selection as a potential source of bias has been 271 
minimised. A prospective randomised trial of iRARC versus ORC recruiting patients 272 
with poor performance status would be the ideal design to test our hypothesis. The 273 
RAZOR (randomized open vs robotic cystectomy) study has finished recruiting and 274 
intends to compare ORC to eRARC for oncological outcomes, complications and 275 
health-related quality of life measures (25).  It is our understanding that the technical 276 
approach for reconstruction in the test arm (RARC) is to convert to open surgery 277 
which may mask the potential advantages of truly minimally invasive surgery. While 278 
the RAZOR trialists are to be commended in overcoming obstacles to the recruitment 279 
to randomised trials of surgical technology, the feasibility of studies large enough to 280 
detect differences in outcomes within in a defined group for e.g. poor 281 
cardiopulmonary performance will be challenging.  In the knowledge that 282 
cardiopulmonary performance status is an independent predictor of outcome in 283 
ORC/eRARC but not iRARC it would therefore seem important account for this and 284 
stratify cases according to performance status. For the present, the apparent lack of 285 
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disadvantage for patients with low performance status can be included as part of the 286 
shared decision making process in clinical practice. 287 
 288 
In common with all other series, experience of iRARC from this centre reflects a 289 
relatively early stage in an evolving technique.  Eight of 14 major adverse events were 290 
classified as 'technical' e.g. hernia, stent migration, anastomotic leak, stricture; and six 291 
as 'non-technical' including sepsis, ileus, cardiac and renal impairment.  While the 292 
major adverse event rate is similar to that reported in other series, it is noted that the 293 
'non-technical' complication rate is lower than in comparable ORC series which is in 294 
keeping with the finding of a lack of relationship between physiological performance 295 
status and adverse outcome (15,19,26).  To date, at our institution, we have performed 296 
over 200 iRARC procedures, which reflects a limited experience.  It is tempting to 297 
suggest that with increasing experience the technical complication rate will decrease 298 
and it will be important to gather evidence in the post learning curve. 299 
 300 
5. Conclusion 301 
The results of this study suggest that in our population of patients undergoing robotic 302 
radical cystectomy with intracorporeal urinary diversion, low cardiorespiratory 303 
reserve did not predict the occurrence of major complications or hospital LOS. The 304 
morbidity and mortality associated with radical cystectomy has reduced in recent 305 
years, and iRARC may present an additional means of improving patient outcomes. 306 
Further research is needed to confirm these results against patients undergoing other 307 
forms of radical cystectomy, but the results are encouraging. 308 
 309 
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Legend to the figure 419 
Figure 1: Flow diagram illustrating case selection 420 
421 
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Figure 1 422 
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Table 1: characteristics of study population including demographics, urinary 424 
diversion type, cardiopulmonary exercise test parameters (CPET), and 425 
clinical outcomes. 426 
 427 
Parameter  Median 
Demographic Age at treatment, median (IQR) 65 (58.75‒71.25) 
 BMI, median (IQR) 27.00 (23.5‒30.5) 
 Male, n (%) 81 (73) 
 Neoadjuvant chemotherapy, n (%) 42 (37.8) 
 
ASA score: ≤2, n (%) 
                    ≥2, n (%) 
69 (84.2) 
13 (15.8) 
Diversion type Ileal conduit, n (%) 80 (72.1) 
 Continent diversion, n (%) 31 (27.9) 
CPET AT, median (IQR) 10 (9‒11) 
 Peak VO2, median (IQR) 15 (12‒18) 
 VE/VC02 (AT), median (IQR) 34 (30‒38) 
Outcomes 
Estimated console time (hours), median 
(IQR) 
5.1 (4-5-6.0) 
 Length of stay (days), median (IQR) 10.0 (7‒13) 
 Major complications at 30 days, n (%) 14 (12.6%) 
 Death 2 
 Multi organ failure 2 
 Abscess 2 
 Gastrointestinal 2 
 Renal failure 6 
 90 day mortality, n (%) 3 (2.70%) 
 Bleed/Sepsis/DIC 1 
 Myocardial infarction 1 
 Carcinomatosis 1 
 428 
429 
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Table 2: Details of major adverse events within 30 days and Clavien-Dindo 430 
Classification. 431 
 432 
Major adverse events within 30 days Outcome Complication type Clavien-Dindo 
Anastomotic stricture,  Nephrostomy and stent insertion Technical 3a 
Migrated stents  Nephrostomy insertion Technical 3a 
Small bowel injury Laparotomy and repair under GA Technical 3b 
Migrated stents  Retrieval under GA Technical 3b 
Port site abscess  Incision and drainage under GA Non-technical 3b 
Pulmonary embolus, para-stomal 
hernia 
Open reduction under GA Technical 3b 
Prolonged Ileus, AKI Medical management Non-technical 4a 
Blocked stent, urinary leak, wound 
dehiscence,  
Laparotomy and repair under GA Technical 4a 
Urinary Sepsis, multi-organ failure Medical management Non-technical 4b 
Urinary Sepsis, multi-organ failure Nephrostomy insertion Non-technical 4b 
Intraoperative rectal injury Intraoperative colostomy 
formation 
Technical 4b 
Migrated stent, sepsis, PICC line 
associated VTE 
Nephrostomy insertion Technical 4b 
Sepsis, bleed, DIC, Hyperkalaemia, 
Death 
Return to theatre for laparotomy Non-technical 5 
MI, death N/A Non-technical 5 
433 
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Table 3: CPET measures for cases with and without major complications at 30 434 
days (Left panel) and correlation between length of stay and CPET parameters 435 
(right panel). 436 
CPET 
measures 
30 day major complication§ Length of stay‡ 
Yes 
(Median) 
No 
(Median) 
P MLogR Rho 95% CI P MLinR 
Anaerobic 
Threshold 
10.5 10 0.762 NS -0.172 -0.372‒0.04 0.122 NS 
Peak VO2 15 17 0.642 NS -0.231 -0.435‒-0.033 0.035 NS 
VE/VC02 (AT) 33.7 34 0.927 NS 0.092 -0.1‒0.289 0.412 NS 
 437 
Key: §=Mann Whitney U test; ‡=Spearman’s correlation; MLogR=Multivariate 438 
logistic regression; MLinR=Multivariate linear regression; NS=Not significant. 439 
Significance level adjusted using Bonferroni method to account for multiple 440 
comparisons such that P=0.016. 441 
 442 
 443 
444 
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Table 4: 30-day major complications (left panel) and length of stay (right panel) 445 
for cases with anaerobic threshold of <11 and those ≥11 (upper rows) (14), and 446 
<12 or ≥12 (lower rows) (15). 447 
 448 
 449 
Anaerobic 
threshold 
30-day major complication Length of stay 
No Yes Chi-Square Median IQR MWU 
<11 40 6 
P=0.911 
11 7.5‒14.5 
P=0.121 
≥11 31 5 10 7‒13 
<12 53 10 
P=0.234 
11 8‒15 
P=0.188 
≥12 18 1 9 8‒12 
 450 
 451 
 452 
 453 
 454 
455 
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Table 5: comparison of present study and published series reporting pre-456 
operative CPET in patients undergoing cystectomy. 457 
 458 
Parameter  Lamb et al Tolchard et al. (13)  Prentis et al. (12) 
 Total, n 111 105 82 
 Analysed, n 82 105 69 
Demographic Age at treatment, mean 65 71 70 
 BMI, mean 27 - 26.9 
 Male, % 81 84 70 
CPEX AT 10.35 (7.0‒19.0) 11.2 (5.8‒22)*† 12.78† 
 Peak VO2 16.11 (7.0‒43.0) 15.2 (9‒27.6) 16.23 
 VE/VC02 (AT) 33.92 (23.0‒48.0) 31 (21‒47.2) ** 36.12 
Outcomes Length of stay (median) 10 10 17.5 
 
Major complications at 30 
days, n (%) 
14 (12.6) - 13 (15.8) 
 90 day mortality, n (%) 3 (2.7) 6 (6) 2 (2.9) 
*=predictive of post-operative complications, significant at P<0.05 level; **=predictive of post-459 
operative complications, significant at P≤0.001 level; †=predictive of hospital length of stay, significant 460 
at P<0.05 level. 461 
